Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Cardiotoxicity × Silymarin × Clear all

Phase

Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Peripheral Nervous System Diseases 1 Gastrointestinal Neoplasms 1 Cognitive Dysfunction 1 Cardiotoxicity 1 Breast Neoplasms 1

Interventions

Trimetazidine 1 Silymarin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡